Number of Cardiologists per Cardiovascular Beds and In-Hospital Mortality for Acute Heart Failure: A Nationwide Study in Japan

Koshiro Kanaoka, MD; Satoshi Okayama, MD, PhD; Michikazu Nakai, PhD; Yoko Sumita; Kenji Onoue, MD, PhD; Tsunenari Soeda, MD, PhD; Kunihiro Nishimura, MD, PhD, MPH; Rika Kawakami, MD, PhD; Hiroyuki Okura, MD, PhD; Yoshihiro Miyamoto, MD, PhD; Satoshi Yasuda, MD, PhD; Hiroyuki Tsutsui, MD, PhD; Issei Komuro, MD, PhD; Hisao Ogawa, MD, PhD; Yoshihiko Saito, MD, PhD

Background—Little evidence is available about the number of cardiologists required for appropriate treatment of heart failure (HF). Our objective was to determine the association between the number of cardiologists per cardiology beds for treating patients with acute HF and in-hospital mortality.

Methods and Results—This was a cross-sectional study, and we used the Japanese Registry of All Cardiac and Vascular Diseases Diagnosis Procedure Combination discharge database. The data of patients with HF on emergency admission from April 1, 2012, to March 31, 2014, were extracted. The patients were categorized into 4 groups by the quartiles of the numbers of cardiologists per 50 cardiovascular beds (first group: median, 4.4 [interquartile range, 3.5–5.0]; second group: median, 6.7 [interquartile range, 6.5–7.5]; third group: median, 9.7 [interquartile range, 8.8–10.1]; and fourth group: median, 16.7 [interquartile range, 14.0–23.8]). Using multilevel mixed-effect logistics regression, we determined adjusted odds ratios for in-hospital mortality. We identified 154 290 patients with HF on emergency admissions. There were 29 626, 36 587, 46 451, and 41 626 patients in the first, second, third, and fourth groups, respectively. HF severity, on the basis of New York Heart Association classification, was similar in the 3 groups. Adjusted odds ratios (95% CIs) for in-hospital mortality were 0.92 (0.82–1.04; P=0.20), 0.82 (0.72–0.92; P<0.001), and 0.70 (0.61–0.80; P<0.001) for the second, third, and fourth groups, respectively. The proportion of medication used, including angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, β blockers, and mineralocorticoid receptor antagonists, was positively correlated to the number of cardiologists.

Conclusions—Patients hospitalized for HF in hospitals with larger numbers of cardiologists per cardiovascular beds had lower 30-day mortality. (J Am Heart Assoc. 2019;8:e012282. DOI: 10.1161/JAHA.119.012282.)

Key Words: cardiologist • database • heart failure • Japanese Registry of All Cardiac and Vascular Diseases • quality assessment

Heart failure (HF) is one of the increasing global problems and leading causes of hospitalization.1–3 The number of hospitalizations with HF is increasing, largely because of an increase in population size and age.4 The mortality from HF has slightly improved because of improved care over the past 10 years, which is probably because medical therapy and circulation devices were widely used.5 However, in-hospital mortality rates from acute HF have remained at the same level in recent years, and the 30-day readmission rate and 5-year mortality of HF are still high.6–8

To further improve the quality of treatments for HF, structural and clinical properties of the hospital, including the physician and case volumes, require more attention. Joynt et al showed that patients with HF cared for by high-volume physicians had lower mortality rates, whereas Ross et al showed that patients with HF cared for by high case volume hospitals had lower risk of in-hospital mortality.9,10 Although high physician volumes led to better outcomes, how to appropriately distribute the physician resources under existing conditions is still incompletely understood. To better understand the relationships between physician resources and HF mortality, we thought that the numbers of

From the Department of Cardiovascular Medicine, Nara Medical University, Nara, Japan (K.K., S.O., K.O., T.S., R.K., H. Okura, Y. Saito); National Cerebral and Cardiovascular Center, Suita, Japan (M.N., Y. Sumita, K.N., Y.M., S.Y., H. Ogawa); Department of Cardiovascular Medicine, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan (H.T.); and Department of Cardiovascular Medicine, The University of Tokyo Graduate School of Medicine, Tokyo, Japan (I.K.).

An accompanying Table S1 is available at https://www.ahajournals.org/doi/suppl/10.1161/JAHA.119.012282

Correspondence to: Yoshihiko Saito, MD, PhD, Department of Cardiovascular Medicine, Nara City Hospital, 1-50-1, Higashikidera-cho, Nara-City, Nara, Japan 630-8305. E-mail: yssaito@naramed-u.ac.jp

Received April 2, 2019; accepted July 30, 2019.

© 2019 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Clinical Perspective

What Is New?

• This was the first study that compared the association between the numbers of cardiologists per cardiovascular bed and the clinical outcomes for acute heart failure.
• Patients with heart failure who were admitted to hospitals with larger numbers of cardiologists per cardiovascular bed were associated with lower in-hospital mortality and higher prescription rates for guideline-based treatments of heart failure.

What Are the Clinical Implications?

• Strategy for the appropriate distribution of cardiologists among hospitals or the development of better transportation system to appropriate hospitals may lead to improvements in the in-hospital outcomes and the quality of care for heart failure.

cardiologists per cardiovascular beds would provide more information. However, there has been no study to clarify whether the larger numbers of cardiologists per cardiovascular beds would lead to better outcomes.

The aim of this study was to clarify the relationships between the number of cardiologists per cardiovascular beds and in-hospital HF mortality.

Materials and Methods

Source of Data and Study Patients

The data, analytic methods, and study materials will not be made available to any researchers for purposes of reproducing the results or replicating the procedure.

This was a cross-sectional study, which used the JROAD (Japanese Registry of All Cardiac and Vascular Diseases) database and JROAD–Diagnosis Procedure Combination (DPC) discharge database.

JROAD is the institutional database, conducted by the Japanese Circulation Society. The data were collected from all training hospitals with cardiovascular beds, and the response rate was 100% each year.11,12 We obtained the following data from the JROAD database: number of hospital beds and cardiologists, presence or absence of cardiac surgery division and coronary care unit, hospital teaching status, and use of ambulance. Barthel index was the assessment tool for activity of daily living. We divided Barthel index on admission into 3 groups: low (0–70), middle (75–95), and high (100), according to a past report.14

We then investigated the rates of the following treatments and clinical outcomes according to the number of cardiologists per cardiovascular beds: prescription rates for medications (angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, β blockers, and mineralocorticoid receptor antagonists), rates for cardiac rehabilitation performance and circulation device use, hospitalization costs, and the length of hospital stay. The multilevel logistic models were used to derive adjusted odds ratio of the prescription rates for medications, using the same covariates. In addition, we

data, such as age and sex, main diagnoses and comorbidities, drugs, diagnostic and therapeutic procedures, length of stay, and patient outcomes.12,13 Of the overall 1620 hospitals included in the JROAD, 808 provided DPC data to the Japanese Circulation Society in 2012 and 2013.

We extracted the patients’ data from JROAD and JROAD-DPC database on the basis of the following inclusion criteria: (1) patients hospitalized in cardiovascular departments because of HF from April 1, 2012, to March 31, 2014; and (2) patients hospitalized on emergency admission. The diagnosis of HF was based on the International Classification of Diseases, Tenth Revision (ICD-10), codes for HF (I50.0, I50.1, and I50.9). Exclusion criteria were as follows: (1) aged <20 years; (2) hospitalized in facilities that treat <10 patients with HF per year; and (3) missing variables.

Statistical Analysis

Data were presented as mean and SD for normally distributed data, median (interquartile range) for nonnormally distributed data, or absolute number (proportion) for categorical data. The patients were categorized into 4 groups by the quartiles of the numbers of cardiologists per 50 cardiovascular beds. The differences among groups were compared using either analysis of variance or Kruskal-Wallis test for continuous variables with Bonferroni correction; or the χ² test for noncontinuous and categorical variables. The main outcome was in-hospital mortality. The association between the number of cardiologists per 50 cardiovascular beds and 30-day mortality was analyzed using multilevel mixed-effect logistics regression, with hospital characteristics at the first level and patient characteristics at the second level. The models were adjusted for the following covariates based on previous reports: age, sex, Charlson comorbidity index, Barthel index, New York Heart Association classification, comorbidities (hypertension, dyslipidemia, diabetes mellitus, chronic kidney disease, and atrial fibrillation), presence of cardiac surgery division and coronary care unit, hospital teaching status, and use of ambulance. Barthel index was the assessment tool for activity of daily living. We divided Barthel index on admission into 3 groups: low (0–70), middle (75–95), and high (100), according to a past report.14

We then investigated the rates of the following treatments and clinical outcomes according to the number of cardiologists per cardiovascular beds: prescription rates for medications (angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, β blockers, and mineralocorticoid receptor antagonists), rates for cardiac rehabilitation performance and circulation device use, hospitalization costs, and the length of hospital stay. The multilevel logistic models were used to derive adjusted odds ratio of the prescription rates for medications, using the same covariates. In addition, we.
performed sensitivity analysis for the main outcome, including the patients without emergency hospitalization, because planned patients were taken care of by the same cardiologists and the distribution of patients with planned admission may affect the results.

A 2-sided \( P < 0.05 \) was considered statistically significant. STATA, Version 14 (Stata Corp, College Station, TX) was used for the analysis.

**Ethics Statement**

This study protocol was approved by the ethical committees in both the Japanese Circulation Society and Nara Medical University (Nara, Japan). The requirement for individual informed consent was waived because no information specifying individuals was included. Data anonymization of the patients’ identifiers was performed in the originally provided DPC data.

**Results**

**Patient Selection**

From April 2012 through March 2014, we identified a total of 224,594 patients with HF in 808 hospitals. We excluded 173,610 patients with acute HF hospitalized in the cardiovascular departments. We excluded 52 patients aged <20 years, 488 patients hospitalized in facilities treating <10 patients with HF per year, and 18,780 patients with missing variables. Consequently, we analyzed 154,290 patients with acute HF in 770 hospitals (Figure 1).

**Hospital Characteristics**

The number of cardiologists per 50 cardiovascular beds (median [interquartile range]) was 4.4 (3.5–5.0), 6.7 (6.5–7.5), 9.7 (8.8–10.1), and 16.7 (14.0–23.8) in the first, second, third, and fourth groups, respectively (Table 1). As the number of cardiologists per 50 cardiovascular beds increased, the following variables also increased: number of patients with HF per facility, hospital beds and cardiologists, presence of cardiac surgery division and coronary intensive care unit, and hospital teaching status. The number of patients with HF per cardiologist was lowest in the fourth group. For each condition, larger numbers of cardiologist hospitals were more likely to provide operations such as coronary interventions, coronary artery bypass grafting, catheter ablation, and pacemaker implantation. They were also more likely to offer clinical examinations, such as echocardiography, coronary computed tomography, magnetic resonance imaging, and radioisotope scintigraphy, for all patients hospitalized at each hospital (Table S1).

**Patient Characteristics**

Approximately 57% of the patients were admitted to the hospitals in the third or fourth groups. By age, they were slightly younger in the larger numbers of cardiologists’ groups. There were minimal differences in Charlson comorbidity index, activities of daily living on admission, and New York Heart Association classification. Diabetes mellitus and dyslipidemia were common in the larger numbers of cardiologists’ groups, whereas atrial fibrillation and chronic obstructive pulmonary disease were common in the smaller numbers of cardiologists’ groups (Table 2).

**In-Hospital Mortality**

Crude in-hospital mortality rates decreased as the number of cardiologists per 50 cardiovascular beds increased: 12% (N=3344), 10% (N=3620), 9% (N=4058), and 7% (N=2848) for the first, second, third, and fourth groups (Table 3). Unadjusted odds ratios (95% CIs) for in-hospital mortality for HF were 0.86 (0.78–0.94; \( P < 0.001 \)), 0.74 (0.67–0.81; \( P < 0.001 \)), and 0.58 (0.52–0.63; \( P < 0.001 \)) for the second, third, and fourth groups, respectively. The estimate of variance for the mixed model was 0.49, with an SE of 0.02 (\( P < 0.001 \)) for the likelihood-ratio test between mixed-effect model and logistic regression model. Adjusted analysis showed that increased number of cardiologists per cardiovascular beds was associated with reduced in-hospital rates of deaths in patients with acute HF. The adjusted odds ratios (95% CIs) for in-hospital mortality were 0.92 (0.81–1.04; \( P = 0.18 \)), 0.81 (0.71–0.91; \( P < 0.001 \)), and 0.68 (0.59–0.77; \( P < 0.001 \)) for the second, third, and fourth groups, respectively (Figure 2). In the sensitivity analysis, we additionally included 3679, 4215, 5581, and 7310 patients with planned admission in the first, second, third, and fourth groups, respectively. The adjusted odds ratios (95% CIs) for in-hospital mortality: 0.92 [0.82–1.04; \( P = 0.21 \)], 0.80 [0.71–0.90; \( P < 0.001 \)], and 0.68 [0.60–0.78; \( P < 0.001 \)] for the second, third, and fourth groups, respectively.

**Treatments for HF**

The prescription rates of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, β-blockers, and mineralocorticoid receptor antagonists were higher in the larger numbers of cardiologists’ groups (Table 3). The adjusted odds ratios for in-hospital medical treatments for patients with HF were as follows. For the second, third, and fourth groups,
adjusted odds ratios (95% CIs) for β-blocker use were 1.09 (0.97–1.22; \( P=0.15 \)), 1.23 (1.09–1.38; \( P<0.001 \)), and 1.59 (1.41–1.81; \( P<0.001 \)), respectively. For angiotensin-converting enzyme inhibitor use, the 3 odds ratios (95% CIs) were 1.04 (0.92–1.17; \( P=0.54 \)), 1.03 (0.91–1.16; \( P=0.62 \)), and 1.38 (1.20–1.58; \( P<0.001 \)), respectively. For mineralocorticoid receptor antagonist use, these odds ratios (95% CIs) were 0.97 (0.87–1.08; \( P=0.59 \)), 1.08 (0.97–1.21; \( P=0.17 \)), and 1.27 (1.13–1.44; \( P<0.001 \)), respectively (Table 4).

A larger number of cardiologists was associated with the higher prescription rate of cardiac rehabilitation, the use of circulation devices (eg, respirators, intra-aortic balloon pump, and percutaneous cardiopulmonary support system), and operations (eg, percutaneous coronary intervention and catheter ablation). These procedures increased as the numbers of cardiologists per 50 cardiovascular beds increased (Table 3).

**Hospitalization Costs and the Length of Hospital Stay**

In comparison with the smaller number of cardiologists’ group, the hospitalization costs in the larger number of cardiologists’ group were higher. The length of hospital stay also increased with the number of cardiologists per 50 cardiovascular beds.

**Table 1. Hospital Characteristics by Category of Cardiologist Numbers per Cardiovascular Beds**

| Characteristics | Total       | First Group | Second Group | Third Group | Fourth Group | \( P \) Value |
|-----------------|-------------|-------------|--------------|-------------|--------------|--------------|
| JCS-certified cardiologists per 50 cardiovascular beds | | | | | | |
| Median (IQR)    | 8.3 (5.7–11.8) | 4.4 (3.5–5.0) | 6.7 (6.5–7.5) | 9.7 (8.8–10.1) | 16.7 (14.0–23.8) | |
| Range           | 0.63–68.6    | 0.63–5.7    | 5.8–8.2      | 8.3–11.8    | 11.9–68.6    | |
| No. (%) of hospitals | 770 | 201 (26) | 177 (23) | 203 (26) | 189 (25) | |
| No. of patients with HF/facilities per y | 152 (97–226) | 113 (77–170) | 150.5 (88–215) | 166 (116–242) | 186 (118–275) | <0.001 |
| No. of patients with HF/cardiologists per y | 43 (28–66) | 59 (41–86) | 51 (34–73) | 40 (28–65) | 26 (13–42) | <0.001 |
| Hospital beds   | 394 (287–547) | 300 (210–366) | 372 (300–466) | 403 (307–539) | 590 (413–749) | <0.001 |
| Cardiovascular beds | 35 (28–45) | 38 (30–48) | 35 (30–45) | 33 (28–40) | 35 (25–45) | 0.03 |
| JCS-certified cardiologists | 4 (3–6) | 3 (2–3) | 4 (3–5) | 4 (3–6) | 7 (5–13) | <0.001 |
| JCS-certified and non-JCS-certified cardiologists | 5 (4–8) | 3 (2–4) | 5 (4–6) | 7 (5–8) | 11 (8–19) | <0.001 |
| Cardiac surgery facilities, % | 59 | 39 | 51 | 64 | 83 | <0.001 |
| Cardiac intensive care units, % | 82 | 68 | 84 | 86 | 90 | <0.001 |
| Hospital teaching status, % | 82 | 67 | 81 | 88 | 91 | <0.001 |

Continuous variables were expressed as median (IQR) for skewed distributed data. Kruskal-Wallis test was used to test for mean differences across groups. Categorical variables were presented as frequencies or percentages and were compared using the \( \chi^2 \) test. HF indicates heart failure; IQR, interquartile range; JCS, Japanese Circulation Society.
group was slightly higher (median hospitalization costs were $6771 [¥744,834], $6890 [¥757,985], $7141 [¥785,572], and $7627 [¥839,057] for the first to fourth groups, respectively). The length of hospital stay was almost the same among groups (Table 3).

### Discussion

In this study, we demonstrated that the numbers of cardiologists per 50 cardiovascular beds were associated with lower in-hospital mortality and higher prescription of guideline-based medical therapy for patients with HF. These findings suggest that optimizing the number of cardiologists per cardiovascular beds is needed, and these results provide useful information for optimizing physician resources to reduce the mortality caused by HF.

This was the first study that compared the association between the numbers of cardiologists per cardiovascular bed and the clinical outcomes. Our results are generally consistent with previous studies, which investigated the effect of absolute numbers of physicians on quality of treatment. Although the present study is an observational study and, thus, it is impossible to clarify the cause-effect relationship, there may be some advantages of a larger number of cardiologists per cardiology beds and some disadvantages of a smaller number.

An earlier study\(^{10}\) showed that the mortality in patients with HF who were admitted to hospitals with higher physician volume per hospital was lower, probably because physicians in high-volume hospitals may be more skilled in decision making about medication use. Other studies showed that patients admitted with acute HF were recommended to be seen for cardiology services; and the larger numbers of

### Table 2. Patient Characteristics by the Number of Cardiologists per Cardiovascular Beds

| Characteristics                              | Total       | First Group | Second Group | Third Group | Fourth Group | P Value |
|----------------------------------------------|-------------|-------------|--------------|-------------|-------------|---------|
| JCS-certified cardiologists per 50 cardiovascular beds Median (IQR) | 8.3 (5.7–11.8) | 4.4 (3.5–5.0) | 6.7 (6.5–7.5) | 9.7 (8.8–10.1) | 16.7 (14.0–23.8) |         |
| Range                                        | 0.63–68.6   | 0.63–5.7    | 5.8–8.2      | 8.3–11.8    | 11.9–68.6    |         |
| No. (%) of patients                          | 150 890     | 29 214 (19) | 35 911 (24)  | 45 526 (30) | 40 239 (27)  |         |
| Age, y                                       | 79±12       | 81±11       | 79±12        | 79±12       | 77±12       | <0.001  |
| Male sex, %                                  | 52          | 48          | 50           | 52          | 54          | <0.001  |
| Charlson comorbidity index                   | 2 (1–3)     | 2 (1–3)     | 2 (1–3)      | 2 (1–3)     | 2 (1–3)     | <0.001  |
| Barthel index, %                             |             |             |              |             |             |         |
| Low (0–70)                                   | 65          | 66          | 64           | 65          | 64          | <0.001  |
| Middle (75–95)                               | 9           | 10          | 10           | 10          | 9           |         |
| High (100)                                   | 26          | 24          | 26           | 25          | 27          |         |
| NYHA classification, %                       |             |             |              |             |             | <0.001  |
| I                                            | 7           | 6           | 6            | 7           | 7           |         |
| II                                           | 26          | 25          | 26           | 27          | 25          |         |
| III                                          | 34          | 37          | 34           | 32          | 34          |         |
| IV                                           | 33          | 34          | 34           | 33          | 34          |         |
| Comorbidities, %                             |             |             |              |             |             | <0.001  |
| Hypertension                                 | 53          | 52          | 53           | 53          | 53          |         |
| Diabetes mellitus                            | 34          | 31          | 33           | 34          | 38          | <0.001  |
| Dyslipidemia                                 | 37          | 31          | 35           | 37          | 44          | <0.001  |
| Chronic kidney disease                       | 12          | 12          | 12           | 11          | 12          | <0.001  |
| Atrial fibrillation                          | 28          | 30          | 28           | 28          | 27          | <0.001  |
| COPD                                         | 12          | 14          | 12           | 11          | 11          | <0.001  |
| Ambulance use, %                             | 40          | 34          | 39           | 42          | 44          | <0.001  |

Continuous variables were expressed as mean±SD for normally distributed data or median (IQR) for skewed distributed data. Analysis of variance or Kruskal-Wallis test was used to test for mean differences across groups. Categorical variables are presented as frequencies or percentages and were compared using the χ² test. COPD indicates chronic obstructive pulmonary disease; IQR, interquartile range; JCS, Japanese Circulation Society; NYHA, New York Heart Association.
cardiologists per hospital beds led to better therapeutic practices in the hospitals with more cardiologists.\textsuperscript{15–17} In fact, in our study, patients with HF admitted to larger numbers of cardiologist hospitals more commonly underwent intensive treatments, such as an artificial respirator, intra-aortic balloon pump, and percutaneous coronary intervention. These treatments might be related to better short-term outcomes in patients with HF. In addition, given that contemporary patients with HF are elderly people with multiple comorbidities, multidisciplinary medical treatment and care should be provided by the heart team, consisting of healthcare professionals from varied fields. Generally, in Japan, the heart team medical service is being developed in large hospitals, which usually comprise many cardiologists.

### Table 3. Treatments and Outcomes by the Numbers of Cardiologists per Cardiovascular Beds

| Variable | Total | First Group | Second Group | Third Group | Fourth Group | \(P\) Value |
|----------|-------|-------------|--------------|-------------|--------------|-------------|
| JCS-certified cardiologists per 50 cardiovascular beds | Median (IQR) | 8.3 (5.7–11.8) | 8.3 (5.7–7.5) | 8.3 (5.7–11.8) | 8.3 (5.7–11.8) | <0.001 |
| Range | 0.63–68.6 | 0.63–5.7 | 5.8–8.2 | 8.3–11.8 | 11.9–68.6 | <0.001 |
| No. (%) of patients | 150 890 | 29 214 (19) | 35 911 (24) | 45 526 (30) | 40 239 (27) | <0.001 |

### Medication, %

| Medication | Total | First Group | Second Group | Third Group | Fourth Group | \(P\) Value |
|------------|-------|-------------|--------------|-------------|--------------|-------------|
| ACE inhibitors or ARBs | 60 | 56 | 60 | 60 | 67 | <0.001 |
| \(\beta\) Blockers | 56 | 48 | 53 | 57 | 65 | <0.001 |
| Mineralocorticoid receptor antagonists | 48 | 46 | 46 | 48 | 53 | <0.001 |
| Calcium channel blockers | 37 | 34 | 35 | 36 | 39 | <0.001 |
| Statins | 29 | 24 | 27 | 29 | 35 | <0.001 |
| Oral hypoglycemic agents | 19 | 17 | 19 | 19 | 21 | <0.001 |
| Loop diuretics | 88 | 86 | 88 | 87 | 89 | <0.001 |
| Thiazide | 11 | 9 | 10 | 11 | 13 | <0.001 |
| Tolvaptan | 12 | 10 | 12 | 11 | 12 | <0.001 |
| Cardiac rehabilitation | 25 | 19 | 20 | 25 | 34 | <0.001 |

### Device use and operation, %

| Device use and operation | Total | First Group | Second Group | Third Group | Fourth Group | \(P\) Value |
|--------------------------|-------|-------------|--------------|-------------|--------------|-------------|
| Respirator | 19 | 15 | 18 | 19 | 23 | <0.001 |
| IABP | 0.8 | 0.3 | 0.7 | 1 | 1.2 | <0.001 |
| VA-ECMO | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | <0.001 |
| CRRT | 1.5 | 1.3 | 1.5 | 1.4 | 1.6 | <0.001 |
| PCI | 4.3 | 3.5 | 3.9 | 4.5 | 4.9 | <0.001 |
| Ablation | 0.2 | 0.1 | 0.2 | 0.2 | 0.3 | <0.001 |
| Length of hospital stay, days | 18 (11–27) | 19 (12–31) | 18 (12–29) | 17 (11–26) | 17 (11–25) | <0.001 |
| Hospitalization cost, $ | 7133 (4786–11 156) | 6771 (4543–10 522) | 6890 (4626–10 709) | 7141 (4808–11 126) | 7627 (5099–12 121) | <0.001 |
| Discharge destination, % | Home | 78 | 75 | 78 | 79 | 80 | <0.001 |
| Other hospitals | 9 | 8 | 8 | 9 | 10 | <0.001 |
| Nursing homes | 4 | 5 | 4 | 3 | 2 | <0.001 |
| In-hospital death | 10 | 12 | 10 | 9 | 7 | <0.001 |

Continuous variables were expressed as median (IQR) for skewed distributed data. Kruskal-Wallis test was used to test for mean differences across groups. Categorical variables are presented as frequencies or percentages and were compared using the \(\chi^2\) test. ACE indicates angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; CRRT, continuous renal replacement therapy; VA-ECMO, venoarterial-extracorporeal membrane oxygenation; IABP, intra-aortic balloon pumping; IQR, interquartile range; JCS, Japanese Circulation Society; PCI, percutaneous coronary intervention. $1\equiv ¥110$. DOI: 10.1161/JAHA.119.012282
We showed that the prescription rates for guideline-based medical treatments, such as angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, β blockers, and MRAs, were lower in the small numbers of cardiologists per cardiovascular beds groups, even after adjustment for patient and hospital characteristics. Guideline-based medical therapies led to better long-term outcomes for patients with HF, and are strongly recommended for the smaller numbers of cardiologists per cardiology beds groups.

In summary, our study showed that many cardiologists per cardiovascular beds leads to significantly reduced in-hospital mortality caused by acute HF, which was consistent with the results of past studies. It might be difficult to increase the absolute number of cardiologists soon; however, an alternative can be considered in terms of strategy for appropriate distribution of cardiologists among hospitals or the development of a better transportation system to appropriate hospitals for patients with HF, which may lead to improvements in the in-hospital outcomes and the quality of care for HF.

Study Limitations
Our study has several limitations. First, this was an observational study using the administrative database, which included ≈50% of Japanese Circulation Society–certified hospitals in Japan. Second, the JROAD-DPC did not include detailed patients’ characteristics, such as laboratory and physiological data. Third, we could not investigate the long-term mortality and accurate rehospitalization rates in this study. The prescription rates for medications and cardiac rehabilitation were higher in the larger numbers of cardiologists’ groups, which may result in better long-term outcomes.

Conclusions
Patients with HF who were admitted to hospitals with larger numbers of cardiologists per cardiovascular bed were

Table 4. Adjusted In-Hospital Medical Treatments for Patients With HF

| Group       | Numbers of Cardiologists per 50 Cardiovascular Beds | β Blockers | ACE Inhibitors or ARBs | MRAs |
|-------------|-----------------------------------------------------|------------|------------------------|------|
|             |                                                     | OR 95% CI  | P Value                | OR 95% CI  | P Value | OR 95% CI  | P Value |
| First       | 0.63–5.7                                            | 1 Reference|                       | 1 Reference|        | 1 Reference|        |
| Second      | 5.8–8.2                                             | 1.09 0.97–1.22 | 0.15 | 1.04 0.92–1.17 | 0.54 | 0.97 0.87–1.08 | 0.59 |
| Third       | 8.3–11.8                                           | 1.23 1.09–1.38 | <0.001 | 1.03 0.91–1.62 | 0.62 | 1.08 0.97–1.21 | 0.17 |
| Fourth      | 11.9–68.6                                           | 1.59 1.41–1.81 | <0.001 | 1.38 1.20–1.58 | <0.001 | 1.27 1.13–1.44 | <0.001 |

Model includes age (per 10 years), sex, Charlson comorbidity index, Barthel index, New York Heart Association classification, hypertension, hyperlipidemia, diabetes mellitus, chronic kidney disease, atrial fibrillation, cardiac surgery, coronary care unit, hospital teaching status, and ambulance use. ACE indicates angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; HF, heart failure; MRA, mineralocorticoid receptor antagonist; OR, odds ratio.
associated with lower in-hospital mortality and higher prescription rates for guideline-based treatments of HF.

Disclosures

None.

References

1. Blecker S, Paul M, Taksler G, Ogedegbe G, Katz S. Heart failure–associated hospitalizations in the United States. J Am Coll Cardiol. 2013;61:1259–1267.
2. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Pool- Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K; ESC Committee for Practice Guidelines (CPG). ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology: developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008;29:2388–2442.
3. Shiba N, Shimokawa H. Chronic heart failure in Japan: implications of the JROAD study. Vasc Health Risk Manag. 2008;4:103–113.
4. Conrad N, Judge A, Tran J, Mohseni H, Hedgecott D, Crespillo AP, Allison M, Munir MB, Sharbaugh MS, Thoma FW, Nisar MU, Kamran AS, Althouse AD, Fi- ranka J, Roger VL. A contemporary appraisal of the heart failure epidemic in the United States. Circulation. 2018;138:965–967.
5. Yasuda S, Nakao K, Nishimura K, Miyamoto Y, Sumita Y, Shishido T, Anzai T, Tsutsui H, Ito H, Komuro I, Saito Y, Ogawa H; on behalf of JROAD Investigators. The current status of cardiovascular medicine in Japan: analysis of a large number of health records from a nationwide claim-based database, JROAD-DPC. Circ J. 2016;80:2327–2335.
6. Akintoye E, Briasoulis A, Egbe A, Dunlay SM, Kushwaha S, Levine D, Afonso L, Fi- ranka J, Roger VL. A contemporary appraisal of the heart failure epidemic in the United States. Circulation. 2018;138:965–967.
7. Soyknanaga H, Hde I, Imamura T, Ohe K. Impact of the Japanese diagnosis procedure combination-based payment system on cardiovascular medicine-related costs. Int Heart J. 2005;46:855–866.
8. Uyttenboogaart M, Stewart RE, Vroomen PC, De Keyser J, Luijckx GJ. Optimizing cutoff scores for the Barthel index and the modified Rankin scale for defining outcome in acute stroke trials. Stroke. 2005;36:1984–1987.
9. Wise J. Acute heart failure patients should be seen by specialist teams, says NICE. BMJ. 2014;348:g3072.
10. Sasaki N, Kunisawa S, Otsubo T, Ikai H, Fushimi K, Yasumura Y, Kimura T, Imanaka Y. The relationship between the number of cardiologists and clinical practice patterns in acute heart failure: a cross-sectional observational study. BMJ Open. 2014;4:e005988.
11. Philbin EF, Weil HF, Erb TA, Jenkins PL. Cardiology or primary care for heart failure in the community setting: process of care and clinical outcomes. Chest. 1999;116:346–354.
12. Konikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieke B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P; ESC Scientific Document Group. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC): developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2018;37:2129–2200.
13. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, Drazner MH, Filippatos GS, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi FA, McBride PE, Peterson PN, Stevenson LW, Westlake C. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136: e137–e161.
14. Japanese Registry of All Cardiac and Vascular Diseases (JROAD). Survey on medical cardiovascular disease 2016. http://www.j-circ.or.jp/jittai_chosa/ jittai_chosa2016web.pdf. Accessed November 10, 2018.
SUPPLEMENTAL MATERIAL
Table S1. Hospital characteristics by category of cardiologist number per cardiovascular beds.

|                                | Total | 1st group | 2nd group | 3rd group | 4th group | p      |
|--------------------------------|-------|-----------|-----------|-----------|-----------|--------|
| **JCS-certified cardiologists** |       | 8.3 (5.7-11.8) | 4.4 (3.5-5.0) | 6.7 (6.5-7.5) | 9.7 (8.8-10.1) | 16.7 (14.0-23.8) |
| per 50 cardiovascular beds      |       |           |           |           |           |        |
| **Median (IQR)**                |       |           |           |           |           |        |
| **Range**                       | 0.63-68.6 | 0.63-5.7 | 5.8-8.2 | 8.3-11.8 | 11.9-68.6 |        |
| **Number of hospitals (%)**     | 770   | 201 (26) | 177 (23) | 203 (26) | 189 (25) |        |
| **Emergent PCI/year**           | 50 (26-89) | 29 (12-46) | 47 (25-74) | 68 (38-103) | 80.5 (43.5-122) | <.001 |
| **Planned PCI/year**            | 132 (66-220.5) | 65 (34-125) | 106 (64-189) | 144 (90-237) | 201 (134-288) | <.001 |
| **CABG/year**                   | 23 (12-41) | 11 (0-20) | 23 (12-38) | 22 (8-39) | 33 (20-53) | <.001 |
| **Catheter ablation/year**      | 2 (0-39) | 0 (0-1) | 0 (0-14.5) | 4 (0-36) | 60 (6-132) | <.001 |
| **Endomyocardial biopsy/year**  | 1 (0-6) | 0 (0-1) | 1 (0-4) | 2 (0-8) | 5 (1-18) | <.001 |
| **Pacemaker implantation/year** | 26 (13-41) | 15 (9-26) | 22 (14-36) | 30 (18-44) | 39 (24-55) | <.001 |
| **CRT/year**                    | 0 (0-4) | 0 (0-0) | 0 (0-0.5) | 0 (0-6) | 6 (0-14) | <.001 |
| **TTE/year**                    | 3037 | 2098 | 2722 | 3305 | 5147 |        |
|                                | (1940-4920) | (1400-2953) | (1894-4129) | (2182-4864) | (3538-7323) |        |
|                      | 200 (84-358) | 120 (50-276) | 182 (77-319) | 211 (100-357) | 294 (147-499) | <.001 |
|----------------------|--------------|--------------|--------------|--------------|--------------|-------|
| Coronary CT/year     |              |              |              |              |              |       |
| Cardiac MRI/year     | 2 (0-21)     | 0 (0-3)      | 1 (0-8)      | 3 (0-17)     | 31 (2-81)    | <.001 |
| Cardiac RI/year      | 188 (78-384) | 94 (24-197)  | 159.5 (54.5-261) | 192 (91-410.5) | 345 (178-556) | <.001 |
| Cardiac rehabilitation/year | 185 (77-369) | 107 (34-103) | 166 (69-284) | 190 (77-383) | 298 (158-485) | <.001 |

Continuous variables were expressed as median (IQR) for skewed distributed data. Kruskal-Wallis test was used to test for mean differences across groups. Categorical variables are presented as frequencies or percentages and were compared using the $\chi^2$ test.

JCS, Japanese Circulation Society; IQR, interquartile range; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; CRT, cardiac resynchronization therapy; TTE, Trans thoracic echocardiography; CT, computed tomography; MRI, magnetic resonance imaging; RI, radioisotope scintigraphy.